International Journal of Pharmacology1811-77751812-5700Asian Network for Scientific Information10.3923/ijp.2018.866.872LiuYuanyuan ShenHaili 62018146Background and Objective: Osteoporosis is a chronic progressive skeletal disorder characterized by low Bone Mass Density (BMD) and bone quality. This study was aimed to access the anti-osteoporotic effects of salvianolic acid B (SAB-B) against ovariectomy-induced in rat model. Materials and Methods: Forty female (n = 40) rats were randomly chosen and divided into four groups as sham-operated control (underwent bilateral laparotomy; sham group, n=10), whereas rats underwent laparotomy followed by bilateral ovariectomy (ovariectomy model group; OVX, n= 10). Whereas, OVX underwent rats were orally supplemented with either 20 or 40 mg kg1 of SAB-B (OVX+20 or 40 mg kg1 SAB-B group; n= 10) for 12 weeks after 4 weeks of OVX. Statistical difference between the experimental groups were analyzed by student t-test using SPSS software at p<0.05. Results: Treatment with SAB-B (20 or 40 mg kg1), substantially increased the body weight than OVX rats. A pronounced elevation in the levels of Bone Mineral Density/Content (BMD/BMC) and body weight were observed in SAB-B treated group as compared to OVX group. Bone markers like deoxypyridinoline, alkaline phosphatase and osteocalcin as well as inflammatory markers like IL-1β, IL-6, TNF-α concentrations were significantly abolished after 12 weeks of administration with SAB-A in OVX rats. Furthermore, the bone biomechanical stability was notably improved upon supplementation with SAB-B. Conclusion: Both SAB-B 20 and 40 mg kg1 treatment exhibit potent anti-osteoporotic activity, nevertheless SAB-B 40 showed superior anti-osteoporotic activity than SAB-B 20. Therefore, SAB-B would be recommended for treating post-menopausal osteoporosis with other standard drugs.]]>Effendy, N.M., I.I. Nurul, M. Norazlina and N.S. Ahmad,201511177200Zhao, X.L., Y.X. Feng and Y. Peng,20124265270Chen, P., Z. Li and Y. Hu,20162016Si, L., T.M. Winzenberg, Q. Jiang, M. Chen and A.J. Palmer,20152619291937Lerner, U.H.,200685584595Weitzmann, M.N. and R. Pacifici,200611611861194Lim, S.Y. and M.B. Bolster,201527216224Lei, W. and W. Chuan,201511148151Abrahamsen, B.,201086421435Wang, Z.Q., J.L. Li, Y.L. Sun, M. Yao and J. Gao et al.,20132013An, J., H. Yang, Q. Zhang, C. Liu, J. Zhao, L. Zhang and B. Chen,20161474658Liu, Z., S. Xu, X. Huang, J. Wang and S. Gao et al.,201517256615675Guo, Y., Y. Li, L. Xue, R.P. Severino and S. Gao et al.,2014Salvia miltiorrhiza: An ancient Chinese herbal medicine as a source for anti-osteoporotic drugs. ]]>J. Ethnopharmacol.,14011416Ma, Z.G., H.Q. Xia, S.L. Cui and J. Yu,20172017Chen, J., W. Zhou, Z. Zhou, T. Yuan, B. Li and Y. Zheng,20171624312438Raoufi, S., T. Baluchnejadmojarad, M. Roghani, T. Ghazanfari, F. Khojasteh and M. Mansouri,20155318031809Zhang, J.M., J. Li, E.W. Liu, H. Wang and G.W. Fan et al.,20162016Xu, D., L. Xu, C. Zhou, W.Y. Lee, T. Wu, L. Cui and G. Li,20145119Cui, L., T. Li, Y. Liu, L. Zhou and P. Li et al.,20122012Zhang, R., S.J. Hu, C. Li, F. Zhang, H.Q. Gan and Q.B. Mei,2012Achyranthes bidentata root extract prevent OVX-induced osteoporosis in rats.]]>1391218Fu, J., H.B. Fan, Z. Guo, Z. Wang, X.D. Li, J. Li and G.X. Pei,2014188222230Lamas, A.Z., I.F. Caliman, P.L.M. Dalpiaz, A.F. de Melo Jr. and G.R. Abreu et al., 2015124101109Sipos, W., P. Pietschmann, M. Rauner, K. Kerschan-Schindl and J. Patsch,2009159230234Abuohashish, H.M., M.M Ahmed, S.S. Al-Rejaie and K.E.H. Eltahir,201536209220Yang, F., Z. Chen, Z. Lian, Y. Guo, G. Liu and G. Dong,2009in vivo.]]>2009Law, Y.Y., H.F. Chiu, H.H. Lee, Y.C. Shen, K. Venkatakrishnan and C.K. Wang,20167902912Shuid, A.N., L.L. Ping, N. Muhammad, N. Mohamed and I.N. Soelaiman,2011Labisia pumila var. alata on bone markers and bone calcium in a rat model of post-menopausal osteoporosis.]]>133538542Cui, Y., B. Bhandary, A. Marahatta, G.H. Lee and B. Li et al.,2011Salvia miltiorrhiza ethanol extract as an anti-osteoporotic agent.]]>2011